Diagnóstico Diabetes Mellitus Síntomas + Glicemia al azar > = 200 mg/dl Asintomático + glicemia en ayunas > = 126 mg/dl Asintomático + Glicemia test >

Slides:



Advertisements
Similar presentations
Type 2 Diabetes Glucose Management Goals 1. AACE Comprehensive Diabetes Care: Glucose Goals ParameterTreatment Goal for Nonpregnant Adults A1C (%)Individualize.
Advertisements

In-Patient Management of Hyperglycemia Rey Vivo, MD Assistant Professor of Medicine Texas Tech University Health Sciences Center.
Conflict of interest Type 1 diabetes >20 years - age 23 Pens: -Aspartate insulin (Novorapid): GM human; 3 X 12 units -Glargine (Lantus): GM human: 36.
1/03/09 De 89 à 98. 1/03/09 De 89 à 98 1/03/09 De 89 à 98.
Insulin Therapy and GLP-1 analogues Dr. Spurgeon Dept of Endocrinology, Christian Medical College, Vellore.
Questions Diabetes. 48. NIDDM response The figure below shows the ‘normal’ response of blood glucose (solid line) and insulin (dashed line) concentrations.
Management of Inpatient Blood Glucose at Temple Housestaff Orientation 2014.
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus Matthew Faiman.

Titrating Insulin to Glycemic Target Judy Bowen, MD CIM Rotation September, 2006.
DIABETES MELLITUS Current diagnostic criteria Diabetes symptoms (polyuria, polydipsia, unexplained weight loss) plus: – Random venous plasma glucose 200.
Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.
Use of Insulin in treatment of diabetes mellitus Prof. Hanan Hagar.
Gestational Diabetes Testing Paradigms in a Rural Office November 7, 2014.
New Insulin Formulations
GDM-DEFINITION Gestational Diabetes Mellitus (GDM) is defined as ‘carbohydrate intolerance with recognition or onset during pregnancy’, irrespective of.
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Combination Therapy for Type 2 Diabetes Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia Presented in Dalton, GA on Aug 14, 2003.
Vascular Effects of Insulin: Implications for Hyperglycemia Management.
Diabetes Prevention Program (DPP)
INSULIN & ORAL HYPOGLYCEMIC AGENTS.
Part 6.

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.
。 33 投资环境 3 开阔视野 提升竞争力 。 3 嘉峪关市概况 。 3 。 3 嘉峪关是一座新兴的工业旅游城市,因关得名,因企设市,是长城文化与丝路文化交 汇点,是全国唯一一座以长城关隘命名的城市。嘉峪关关城位于祁连山、黑山之间。 1965 年建市,下辖雄关区、镜铁区、长城区, 全市总面积 2935.
Use of Insulin in the treatment of diabetes mellitus Prof. M.Alhumayyd.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
10/3/2014. Εμφραγμα - Στηθαγχη - Πονος στο στηθος : Εμφραγμα μυοκαρδιου λεμε την βαρυτατη εκεινη κατασταση που οφειλεται στην αποφραξη που μπορει να γινει.
Use of Insulin in the treatment of diabetes mellitus
Protocol for the management of adult patients with DKA
Type 1 Diabetes Mellitus
به نام خدا دارو درمانی دیابت
The 75 g glucose loading test.
Protocol for management of adult patients with DKA or HHS
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Protocol for the management of adult patients with HHS
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Hypothalamic Hormones
Protocol for the management of pediatric patients (250 mg/dl, venous pH
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Level of risk factor control in the overall sample and by gender
Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Protocol for the management of adult patients with DKA
Development of stable STZ-induced diabetes requires coexisting diet-induced impaired glucose tolerance. Development of stable STZ-induced diabetes requires.
One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.
Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.
Comparison of the protective effects of R and S isomers of LA on insulin-stimulated 2-DG uptake. Comparison of the protective effects of R and S isomers.
Prevalence of diabetes (DM) after pancreaticoduodenectomy for PDAC
The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.
A and B: Glucose reabsorption via SGLT1 and SGLT2 in normal and diabetic kidney. A and B: Glucose reabsorption via SGLT1 and SGLT2 in normal and diabetic.
Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.
A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:
Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.
Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.
Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.
Arterial and portal plasma glucagon levels and the portal-arterial (P-A) glucagon gradient in the control period (−40 to 0 min) and after administration.
The portal-arterial (P-A) insulin gradient and arterial plasma c-peptide levels in the control period (−40 to 0 min) and after administration of the glycogen.
Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.
Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.
Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.
Protocol for the management of pediatric patients (250 mg/dl, venous pH
Protocol for Management of Adult Patients with Diabetic Ketoacidosis
Insulin Delivery Systems Atlanta Diabetes Associates
The continuous line represents the sensor glucose values.
© The Author(s) Published by Science and Education Publishing.
Glucose log of a 51-year-old patient with insulin-requiring type 2 diabetes and an A1C of 7.8% who takes 10 mg of glyburide at bedtime and 25 units of.
Cumulative mean numbers of confirmed (plasma glucose ≤3
Presentation transcript:

Diagnóstico Diabetes Mellitus Síntomas + Glicemia al azar > = 200 mg/dl Asintomático + glicemia en ayunas > = 126 mg/dl Asintomático + Glicemia test > = 200 mg/dl Glicemia basal alterada: Glicemia mg/dl Intolerancia glucosa : Glicemia mg/dl con test

Dosis fármacos Dosis InicioDMD Glibenclamida2.5 mg15 mg Metformina500 mg2550 mg Rosinglitazona48 Acarbosa25 mg /8200 c/8

Nombre Genérico Inicio (h) Dura- ción (h) Vida Media (h) Dosis Adultos Dosis Ancianos DMDMetab olis- mo Excre -ción Tolbuta- mida ,61 – 2 g500 mg2-3 g Hepátic o Metab orina Clorpro- Pamida mg100 mg500 mg Hepátic o Inalterad orina Gliben- Clamida 1, – 45 mg2,5 mg20 mg Hepátic o Orina y heces Glipi- zida – 75 mg2,5 – 5 mg40 mg Hepátic o Metab. Orina Metfor- Mina 1, ,5– mg3 g Urinaria Acar- bosa 2,8300 mg intestinoMetab. heces

TIPOSINICIOPick Máximo (hr) Duración Efectiva (hr) Duración Máxima (hr) Vía de adminis- tración LISPRO5-15 min½ - 1½ – 5Sc, ev, im RAPIDA½ h - 1h2- 33 – 64 – 6Sc, ev, im NPH2 – 4 h4 – 1010 – 1614 – 18sc LENTA3 – 4 h4 – 1212 – 1816 – 20sc ULTRALENTA6 – 10 h